Results 21 to 30 of about 13,357,463 (271)

Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis [PDF]

RMD Open, 2020
Objectives Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA), despite lacking clear evidence.
Ilja Tchetverikov, J M W Hazes, Hannah den Braanker, Kim Wervers, Adriana M C Mus, Priyanka S Bangoer, Nadine Davelaar, Jolanda Luime, Marijn Vis, Erik Lubberts, Marc R Kok   +10 more
doaj   +2 more sources

Minimal Disease Activity as a Therapeutic Goal in Atopic Dermatitis: Predictive Factors of Sustainability in a Multicenter Cohort [PDF]

Dermatology and Therapy
Introduction Minimal disease activity (MDA) is an emerging therapeutic goal in atopic dermatitis (AD), providing a multidimensional assessment of disease control. Methods We conducted a retrospective multicenter study of adults with moderate-to-severe AD
Francisco Javier Melgosa Ramos, Santiago Guillén Climent, Marta Galarreta Pascual, Antonio Martorell, María Matellanes Palacios, Juncal Roca Ginés, Javier Sabater Abad, Eduardo Bernia Petit, Víctor González Delgado   +8 more
doaj   +2 more sources

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity [PDF]

BMC Rheumatology, 2018
Background Although psoriatic arthritis is complex and involves multiple domains, recent advances in treatments have made remission or near-remission of most symptoms a potentially achievable goal for many patients.
Laura C. Coates, Ana-Maria Orbai, Akimichi Morita, Olivier Benichou, Lisa Kerr, David H. Adams, Catherine L. Shuler, Julie Birt, Philip S. Helliwell   +8 more
doaj   +2 more sources

Longitudinal Instability of Minimal Disease Activity Domains in Psoriatic Arthritis with Fluctuating Response: A Trajectory Analysis of a Real-World Cohort [PDF]

Rheumatology and Therapy
Introduction Minimal disease activity (MDA) is a composite tool used to measure disease state in psoriatic arthritis (PsA), but its longitudinal stability across individual domains remains insufficiently understood.
Mauro Fatica, Fabio Massimo Perrotta, Noemi Italiano, Eneida Çela, Maria Sole Chimenti, Ennio Lubrano   +5 more
doaj   +2 more sources

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study [PDF]

BMC Rheumatology
Background To explore the trajectory of, and factors contributing to, achievement of individual criteria of minimal disease activity (MDA) in patients with active psoriatic arthritis (PsA) treated with guselkumab. Methods The Phase 3, randomized, placebo-
Laura C. Coates, Proton Rahman, Philip J. Mease, May Shawi, Emmanouil Rampakakis, Alexa P. Kollmeier, Xie L. Xu, Soumya D. Chakravarty, Iain B. McInnes, Lai-Shan Tam   +9 more
doaj   +2 more sources

Improving the outcome of psoriatic arthritis [PDF]

, 2010
Psoriatic arthritis (PsA) is recognised to have a significant impact on functional impairment, joint damage and quality of life. The aim of this thesis was to investigate tools for early identification, to develop a clinical target for treatment and to ...
Coates, Laura Claire
core   +6 more sources

The level of urinary semaphorin3A is associated with disease activity in patients with minimal change nephrotic syndrome

International Journal of Nephrology and Renovascular Disease, 2017
Akiko Inoue-Torii,1 Shinji Kitamura,1 Jun Wada,1 Kenji Tsuji,2 Hirofumi Makino1 1Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; 2Center for Systems ...
Inoue-Torii A, Kitamura S, Wada J, Tsuji K, Makino H   +4 more
doaj   +3 more sources

Influence of the duration of psoriatic arthritis on the achievement of remission and minimal disease activity during therapy with genetically engineered biologic drugs. Data from the all-russian register of patients with psoriatic arthritis

Научно-практическая ревматология, 2021
Aim. To study the frequency and timing of the onset of remission and minimal disease activity after the administration of genetically engineered biologic drugs (GEBD) in patients with early and long-term psoriatic arthritis observed within the framework ...
E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, Yu. L. Korsakova, M. V. Sedunova, I. N. Pristavskiy, I. N. Kushnir, I. F. Umnova, S. S. Kudishina, E. L. Nasonov   +9 more
doaj   +1 more source

Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study

Rheumatology and Therapy, 2022
Plain Language Summary Psoriatic disease is a group of heterogeneous inflammatory conditions, mainly affecting patients’ skin and joints. Among the few biomarkers associated with inflammation in psoriatic disease, serum calprotectin may be a promising ...
Borui Li, Guangtao Li, Zhibo Song, Zhuoli Zhang   +3 more
doaj   +1 more source

Residual disease activity in psoriatic arthritis: discordance between the rheumatologist’s opinion and minimal disease activity measurement [PDF]

Rheumatology, 2017
To assess how many PsA patients with an acceptable disease state according to the treating rheumatologist have quiescent disease defined as minimal disease activity (MDA).This cross-sectional study included 250 PsA patients. To assess current clinical practice as closely as possible, acceptable disease state was not determined by predefined activity ...
van Mens, Leonieke J J, Turina, Maureen C, van de Sande, Marleen G H, Nurmohamed, Mike T, van Kuijk, Arno W R, Baeten, Dominique L P   +5 more
openaire   +3 more sources